| Literature DB >> 32323167 |
Ahmed Mohamed Elhfnawy1,2,3, Doaa Elsalamawy4, Mervat Abdelraouf4, Mira Schliesser5, Jens Volkmann5, Felix Fluri5.
Abstract
Giant cell arteritis (GCA) may affect the brain-supplying arteries, resulting in ischemic stroke, whereby the vertebrobasilar territory is most often involved. Since etiology is unknown in 25% of stroke patients and GCA is hardly considered as a cause, we examined in a pilot study, whether screening for GCA after vertebrobasilar stroke might unmask an otherwise missed disease. Consecutive patients with vertebrobasilar stroke were prospectively screened for GCA using erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin, and halo sign of the temporal and vertebral artery on ultrasound. Furthermore, we conducted a systematic literature review for relevant studies. Sixty-five patients were included, and two patients (3.1%) were diagnosed with GCA. Patients with GCA were older in age (median 85 versus 69 years, p = 0.02). ESR and CRP were significantly increased and hemoglobin was significantly lower in GCA patients compared to non-GCA patients (median, 75 versus 11 mm in 1 h, p = 0.001; 3.84 versus 0.25 mg/dl, p = 0.01, 10.4 versus 14.6 mg/dl, p = 0.003, respectively). Multiple stenoses/occlusions in the vertebrobasilar territory affected our two GCA patients (100%), but only five (7.9%) non-GCA patients (p = 0.01). Our literature review identified 13 articles with 136 stroke patients with concomitant GCA. Those were old in age. Headache, increased inflammatory markers, and anemia were frequently reported. Multiple stenoses/occlusions in the vertebrobasilar territory affected around 70% of stroke patients with GCA. Increased inflammatory markers, older age, anemia, and multiple stenoses/occlusions in the vertebrobasilar territory may be regarded as red flags for GCA among patients with vertebrobasilar stroke.Entities:
Keywords: Blood sedimentation; C-reactive protein; Giant cell arteritis; Hemoglobin; Stenosis; Vertebrobasilar stroke
Mesh:
Year: 2020 PMID: 32323167 PMCID: PMC8423705 DOI: 10.1007/s13760-020-01344-z
Source DB: PubMed Journal: Acta Neurol Belg ISSN: 0300-9009 Impact factor: 2.396
Characteristics of the patients in current study
| Characteristic | All ( | No GCA ( | GCA ( | |
|---|---|---|---|---|
| Baseline | ||||
| Age, years | 69 (31–90) | 69 (31–88) | 85 (80–90) | 0.02* |
| Female sex | 23 (35%) | 22 (35%) | 1 (50%) | 0.59 |
| Hypertension | 54 (83.1%) | 52 (82.5%) | 2 (100%) | 0.69 |
| Diabetes mellitus | 8 (12.3%) | 7 (11.1%) | 1 (50%) | 0.23 |
| Atrial fibrillation | 20 (30.8%) | 19 (30.2%) | 1 (50%) | 0.52 |
| Active smoker | 12 (18.5%) | 12 (19%) | 0 (0%) | 0.66 |
| Previous stroke | 12 (18.5%) | 12 (19%) | 0 (0%) | 0.66 |
| Clinical | ||||
| Acute onset of any headachea | 20 (30.8%) b | 20 (31.7%) | 0 (0%) | 0.46 |
| Acute onset of temporal headachea | 4 (6.2%)b | 4 (6.3%) | 0 (0%) | 0.87 |
| Temporal tenderness | 3 (4.6%)b | 3 (4.8%) | 0 (0%) | 0.91 |
| Thickened temporal artery | 6 (9.2%) | 5 (7.9%) | 1 (50%) | 0.18 |
| History of amaurosis fugax | 2 (3.1%) | 2 (3.2%) | 0 (0%) | 1 |
| NIHSS on admission | 2 (0–42) | 2 (0–42) | 3 (0–6) | 0.48 |
| Good outcome on dischargec | 50 (76.9%) | 49 (77.8%) | 1 (50%) | 0.41 |
| Laboratory investigations | ||||
| ESR (mm after 1 h) | 12 (1–100) | 11 (1–60) | 75 (50–100) | 0.001* |
| CRP (mg/dl) | 0.25 (0.02–7.09) | 0.25 (0.02–7.09) | 3.84 (3.07–4.61) | 0.01* |
| Hemoglobin (g/dl) | 14.5 (8.2–18.6) | 14.6 (8.2–18.6) | 10.4 (10–10.8) | 0.003* |
| Platelets (n*1000/µl) | 246 (85–1272) | 242 (85–1272) | 315 (291–338) | 0.09 |
| Stenosis and/or occlusion in the vertebrobasilar territory | ||||
| One | 21 (32.3%) | 19 (30.2%) | 2 (100%) | 0.1 |
| > = 2 | 7 (10.8%) | 5 (7.9%) | 2 (100%) | 0.01* |
| Atherosclerosis of the internal carotid artery with stenosis < 50% | 42 (64.6%) | 40 (63.5%) | 2 (100%) | 0.41 |
| Atherosclerosis of the internal carotid artery with stenosis ≥ 50% | 4 (6.2%) | 3 (4.8%) | 1 (50%) | 0.12 |
Results are expressed in absolute values (percentage) or median (range)
CRP C-reactive protein, ESR erythrocyte sedimentation rate, GCA giant cell arteritis, NIHSS national institute of health stroke scale
*Statistically significant results
aAcute onset was defined as headache occurring 3 days before or after stroke
bIn three non-GCA patients, history regarding headache was not available and assessment of the temporal tenderness was not possible because of the bad general condition
cGood outcome on discharge was defined as mRS ≤ 2
Fig. 1a, b and c refer to the first patient with giant cell arteries (GCA). a Color-coded duplex examination showing halo sign (hypoechogenicity of the vessel wall) in the left vertebral artery (white arrows). b Ultrasound examination in the power mode showing halo sign of the temporal artery on the right side (white arrows). c Computer tomographic angiogram showing stenosis in the right vertebral artery, representing the “string-of-beads” sign (short thick red arrow) and occlusion of the left vertebral artery (long thin red arrow). d Haematoxylin and eosin staining of a biopsy from the temporal artery of the second patient with GCA showing transmural infiltration of the all wall layers with mixed inflammatory cells consisting of lymphocytes and plasma cells with multinucleated giant cells (long red arrow) (color figure online)
Characteristics of patients with giant cell arteritis at the times of stroke diagnosis in the included studies
| Author, journal | Age (years) | Male sex, | Affection of the VB- territory, | Headache, | ESR (mm after 1 h) or | CRP (mg/dl) or | Hemoglobin (g/dl) | Multiple stenoses/occlusions in the VB- territory, | |
|---|---|---|---|---|---|---|---|---|---|
| Pariente et al. [ | 18 | Median (range) 83 (67–96) | 11 (61.1%) | 11 (61.1%) | 15 (83.3%) | NA | Median (range) 6.6 (1–21.1), increased in 15 (83.3%) | NA | NA, but bilateral in 6 (33.3%) |
| Conway et al. [ | 14 | 70 (63–78) | 7 (50%) | NA | 8 (57.1%) | 53 (36–88), increased in 11 (78.6%) | 4.8 (1.8–10.9), increased in 12 (85.7%) | NA | NA |
| Lago et al. [ | 6 | 71 (63–73) | 3 (50%) | 4 (66.7%) | 4 (66.7%) | 68 (16.5–88.5), increased in 5 (83.3%) | 4.9 (1.7–6.4) Increased in 6 (100%) | Anemia in 2 patients, for the other 4 patients NA | 3 (50%) |
| Chazal et al. [ | 14 (1 with TIA) | Median (range) 73.5 (65–82) | 3 (21.4%) | 6 (42.9%) | 5 (35.7%) | NA | Median (range) 0.6 (0.2–6.8) | NA | NA |
| de Boysson et al. [ | 40 | Median (range) 78 (60–91) | 19 (47.5%) | 29 (72.5%) | 29 (72.5%) | Median (range) 68 (10–119) | Median (range) 6.1 (2.8–18.5) | Anemia in 22/37 (59.5%), in 3 patients data na | 9/12 (75%), in the other patients data NA |
| Alsolaimani et al. [ | 5 | 70 (53–78) | 3 (60%) | 3 (60%) | 5 (100%) | 37 (27.5–91), increased in 3 (60%) | 2.1 (0.9–3.5) increased in 3 (75%), in 1 patient na | NA | 4 (80%) |
Larivière et al. [ Medicine (Baltimore) | 8 | 72 (62–76) | 6 (75%) | 7 (87.5%) | 6 (75%) | NA | 7.3 (4.6–10.7) | NA | 4 (50%) |
| Samson et al. [ | 4 | 82 (80–88) | 3 (75%) | 3 (75%) | 1 (25%) | 56 (42.5–66.5), increased in 2 (50%) | 4.7 (3.3–19.6), increased in 4 (100%) | NA | NA |
| Zenon et al. [ | 6 | 77 (64–83) | 2 (33.3%) | 2 (33.3%) | 5 (83.3%) | 93 (72–100), increased in 6 (100%) | 9.4 (5.3–12.8), increased in 6 (100%) | NA | NA |
| García-García et al. [ | 5 | 79 (77–82) | 2 (40%) | 5 (100%) | 2 (40%) | 60 (40.5–92.5), increased in 4 (80%) | NA | NA | 2 (40%) |
| Boettinger et al. [ | 3 | 73, 74, 65 | 2 (66.7%) | 3 (100%) | 2 (66.7%) | 85, 100, in one patient na | 2.6, 2.3, in one patient NA | NA | 3 (100%) |
| Solans-Laqué et al. [ | 7 | 74 (67–85) | 4 (57.1%) | 5 (71.4%) | 5 (71.4%) | 98 (78–99) | NA | 10.5 (9–11), anemia in 7 (100%) patients | 2/6 (33.3%) (in one patient data NA) |
| Wiszniewska et al. [ | 6 | 80 (74–81) | 5 (83.3%) | 4 (66.7%) | 6 (100%) | 37.5 (9.5–82.5), increased in 3 (50%) | NA | NA | NA |
All results are expressed as median (interquartile range) or absolute numbers (%), unless otherwise specified
CRP C-reactive protein, ESR erythrocyte sedimentation rate, NA not available, TIA transient ischemic attack, VB vertebrobasilar
CRP was considered as increased, if the value was > 0.5 mg/dl
ESR was considered increased if the value was > age/2 for men or age/2 + 10 for women
Studies reporting the prevalence of GCA among patients with stroke
| Author, journal | Total no. of patients with stroke | Type of stroke | Screening method | Study period | Cases diagnosed with GCA | Comment |
|---|---|---|---|---|---|---|
| García-García et al. [ | 1273 patients | Ischemic stroke, either in the anterior or VB-territory | Halo sign of the vertebral artery | Between Mar 2008 to Jan 2010 | 5 patients (0.4%); all in the VB-territory | No data are available regarding the stroke location (anterior or VB-territory) in the screened patients. Assuming that VB-stroke represents 15–20% of all ischemic strokes, the prevalence of GCA might be estimated as 2–2.6% among patients with VB-stroke |
| Wiszniewska et al. [ | 4086 patients in the Lausanne Stroke Registry | First stroke, either ischemic or hemorrhagic | No screening applied, routine work-up | between Jan 1980, and Dec 1998 | 6 patients (0.15%) with ischemic stroke, four of them with affection of the VB-territory | No data are available regarding the stroke type (ischemic or hemorrhagic) or location (anterior or VB-territory) among the screened patients |
GCA giant cell arteritis, VB vertebrobasilar
Fig. 2Proposed flow chart showing the red flags raising suspicion and warranting screeing for giant cell arteritis among patients with vertebrobasilar stroke